Summary of Harbin Pharmaceutical Group 20 12

On February 20 12, Harbin Pharmaceutical Group announced that "Harbin Pharmaceutical Heilongjiang Sales Branch, a subsidiary of the company, and Harbin Pharmaceutical Health Industry Company, a wholly-owned subsidiary, have irregular operations in direct selling business." Harbin Pharmaceutical finally ended its direct selling trip temporarily by "washing its dirty linen in public".

According to the dealer who has done Harbin Pharmaceutical Co., Ltd., Harbin Pharmaceutical Co., Ltd. has completely withdrawn from the direct selling industry, and the background declaration has been closed. In this way, Harbin Pharmaceutical kept its direct sales license and hid it in the industry. It is reported that on the occasion of the launch of Harbin Pharmaceutical Co., Ltd., dealers can voluntarily choose to switch to store operation or return a refund. In the process of re-checking and registering the intention of Harbin Pharmaceutical Co., Ltd., most dealers chose to return the goods for a refund, which Harbin Pharmaceutical Co., Ltd. said would cause a loss of 280 million.

Some dealers believe that this is only the loss reported unilaterally by the company. In fact, many dealers did not complete the return because the return was limited by time, only notified in the background, and there was no open platform. The return is mainly concentrated in the three northeastern provinces.